In an unprecedented move, the Food and Drug Administration (FDA) issued a new draft guidance on September 18, 2023, named “Labeling for Biosimilar and Interchangeable Biosimilar Products”. It replaces their previous labeling guidance “Labeling for Biosimilar Products” from July 2018. Detailed by Venable LLP, the FDA specified significant revisons from the prior guidance.
The agency has yet to reveal all the changes they’ve instituted, as their statement on the topic was not exhaustive. While it did highlight the forward strides they aim to make, it leaves room for speculation regarding the potential impact of these changes, especially on product labels and labeling processes. Given the FDA’s history of regulatory shifts, additional alterations can be expected as this new guidance takes effect.
This significant policy shift carries potential implications for legal professionals specializing in pharmaceutical and healthcare law. It could create a ripple effect through corporate legal departments and law firms who will need to quickly understand and implement changes to ensure compliance with the new and amended regulations. Needless to say, it makes the job of legal professionals even more crucial in their respective litigation and regulatory practices.
While the industry awaits further insights into the specifics of the guidance, it is clear that these changes reflect the FDA’s continued commitment towards ensuring the safety and efficacy of biosimilar products for patients. Understanding and adapting to these significant legislative developments will be critical for both corporate legal departments and law firms across the globe.